Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.
about
Approach to Patients with Severe Asthma: a Consensus Statement from the Respiratory Care Experts' Input Forum (RC-EIF), IranTargeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.Interleukin-31 expression and relation to disease severity in human asthma.Herbal Medicine Cordyceps sinensis Improves Health-Related Quality of Life in Moderate-to-Severe AsthmaOmalizumab therapy for children and adolescents with severe allergic asthma.Real-life Efficacy of Omalizumab After 9 Years of Follow-up.The safety of monoclonal antibodies in asthma.Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders.Asthma biomarkers in the age of biologics.Biologic agents for severe asthma patients: clinical perspectives and implications.RItA: The Italian severe/uncontrolled asthma registry."Real-life" Efficacy and Safety Aspects of Four-year Omalizumab Treatment for Asthma.Monoclonal Antibodies for the Management of Severe Asthma.Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults.Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.Controlling Mast Cell Activation and Homeostasis: Work Influenced by Bill Paul That Continues Today.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Two decades with omalizumab: what we still have to learnTolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up
P2860
Q26777154-67086B7A-2AD2-4D9C-B6A1-D62A40B737EBQ30360362-C3EC916F-161D-4B84-8622-61F63FB5007FQ36599623-EC9C06AA-BA60-40BB-A08B-1959D6715B7BQ36666764-7059B06D-7F93-4809-AD43-52D075F1D29CQ37512643-521B859C-5DEC-4578-8C2E-A956CF700987Q38574776-72F6A4A6-9BBA-4C3B-B66E-F94D83536EB2Q38789811-102C97D6-C010-4CDF-9E34-2AE7665C7255Q38842153-A3E6610C-0E29-4E58-B81B-DDE86E519F7BQ38997626-0A950650-080E-4E9C-8BEF-F160CE343F1BQ39435705-C817076B-7122-4A68-9264-99AC21D55DD0Q47169950-7E2308FF-6388-4134-85A4-A4FF7B7BC42BQ47576873-16B3D5A6-C120-4100-918B-E96473669014Q47598081-D9E52F67-1052-4EA2-82F3-1CAD5FB42335Q50133970-7881D5EF-4F54-4EE7-AE3B-ABF3EDFAAC52Q51687473-28A157E6-D2C0-4913-9919-EA4101A0533BQ52657068-AEC11202-DE68-42EA-8F98-D0B7129355A4Q52691764-3D8C3412-6E43-43A2-94DE-144DE17E7257Q54213225-B04A8961-DAEC-4FFF-B498-E96DA7B7F8FCQ55447639-ADF8FF08-2598-4E45-BD1E-AD40A16BE66AQ59135496-3E387597-BB68-42E9-8D3C-DBD8730DB8DCQ59136709-49AB8054-2EB3-4346-8C67-B7C4C0BF1EC8
P2860
Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Long-term efficacy and safety ...... atic review and meta-analysis.
@ast
Long-term efficacy and safety ...... atic review and meta-analysis.
@en
type
label
Long-term efficacy and safety ...... atic review and meta-analysis.
@ast
Long-term efficacy and safety ...... atic review and meta-analysis.
@en
prefLabel
Long-term efficacy and safety ...... atic review and meta-analysis.
@ast
Long-term efficacy and safety ...... atic review and meta-analysis.
@en
P2093
P2860
P31
P921
P356
P1433
P1476
Long-term efficacy and safety ...... atic review and meta-analysis.
@en
P2093
Chao Zhang
Huahao Shen
Shaobin Wang
Songmin Ying
Tianwen Lai
P2860
P2888
P356
10.1038/SREP08191
P407
P577
2015-02-03T00:00:00Z